No annual revenue total was found in MOONLAKE IMMUNOTHERAPEUTICS's SEC filings.
Moonlake Immunotherapeutics (MLTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$196.0 million. As of Sep 30, 2026 it held $498.5 million in cash and investments and $101.6 million in total debt.
Revenue
—
Net income (TTM)
$-273.48M
-29.9% vs year-ago TTM
Operating cash flow (TTM)
$-244.04M
-31.4% vs year-ago TTM
Free cash flow (TTM)
$-244.04M
-31.3% vs year-ago TTM
EPS (TTM)
$-3.66
-10.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
52.70M
Net cash
$396.85M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$244.8M | -$143.1M | -$54.1M | -$65.1M | -$4.6M |
| Net income | -$227.3M | -$118.9M | -$36.0M | -$50.0M | -$4.5M |
| Diluted EPS | -$3.53 | -$1.89 | -$0.73 | -$1.70 | — |
| Operating cash flow | -$196.0M | -$116.6M | -$42.8M | -$55.9M | -$611,071 |
| Free cash flow | -$196.0M | -$117.1M | -$43.1M | -$55.9M | — |
| Total assets | $424.4M | $477.9M | $526.5M | $76.8M | $9.7M |
| Total liabilities | $120.0M | $24.5M | $13.0M | $8.1M | $21.3M |
| Stockholders' equity | $304.5M | $446.8M | $495.7M | $48.9M | -$11.6M |
| Cash and investments | $394.0M | $448.0M | $511.0M | $72.1M | $8.0M |
| Total debt | $75.7M | $2.8M | $3.7M | $282,580 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
All 331 Moonlake Immunotherapeutics SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.